Pharma BD Deal Intelligence
A $850M acquisition where Johnson & Johnson bought Proteologix outright for drug development, though the deal remains thinly documented—no disclosed assets, molecules, or indications accompany the price tag.
Johnson & Johnson to acquire Proteologix for $850 million to lead in atopic dermatitis treatment with bispecific antibody portfolio
Proteologix Inc to be acquired by Johnson & Johnson for $850 million in cash for bispecific antibody programs in immune-mediated diseases
Johnson & Johnson boosts bispecifics portfolio with Proteologix acquisition gaining ten bispecific antibody programs across multiple diseases
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
J&J acquired Proteologix for $850M for drug development.
200K US cases/yr · $15.0B Global AD Market (2025E)
PX-128 (IL-13/TSLP bispecific) targets moderate-to-severe AD and asthma. PX-130 (IL-13/IL-22) preclinical for AD. Plus 8 additional bispecific programs.
Dupixent ($13B+) dominates. JAK inhibitors growing. Bispecific dual-targeting unproven but could offer differentiated efficacy.
Johnson & Johnson completed a acquisition/merger transaction with Proteologix Inc..
Significant transaction at $850M. J&J acquired Proteologix for $850M for drug development.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Proteologix Inc. (this deal) | 2024 | $850M | 66 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2024 deals · Johnson & Johnson deals · Dermatology deals